W. L. Gore & Associates has announced that it has received the CE mark approval for the commercial distribution of its GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface in the European Union. The device is indicated for the endovascular grafting of peripheral arteries. To treat arterial vascular disease, the device combines the company’s propriety heparin surface with the proven performance of the GORE VIABAHN Endoprosthesis. To keep the heparin attached to the endoprosthesis surface over time the device uses the proprietary end-point surface attachment technology that preserves the heparin bioactive sites such that they remain free to interact with the blood without being consumed. The low-profile delivery system of the device gives interventionalists a more streamlined approach to re-line the peripheral arteries. The GORE VIABAHN Endoprosthesis is constructed with a durable, reinforced, biocompatible, ePTFE liner attached to an external nitinol stent structure. The excellent flexibility of the endoprosthesis enables it to better traverse tortuous areas of the Superficial Femoral Artery and conform more closely to the complex anatomy of the artery.